Giant chondrosarcoma of the falx in an adolescent: A case report
CONCLUSION: This is an unusual case of an extra-axial, non-skull base, low-grade chondrosarcoma presenting as facial spasm in an adolescent patient.PMID:33948308 | PMC:PMC8088535 | DOI:10.25259/SNI_898_2020
Conclusion: Although uncommon, intraspinal mesenchymal chondrosarcomas warrant both radical local resection and aggressive adjuvant therapy with chemoradiation to provide the greatest chance of progression-free survival. PMID: 33030461 [PubMed - as supplied by publisher]
Authors: Gong L, Bui MM, Zhang W, Sun X, Zhang M, Yi D Abstract H3F3A mutations and the expression of glycine 34 to tryptophan (G34W) mutants in giant cell tumors of bone (GCTBs) and other bone tumors were detected to compare H3F3A mutation types and the expression of G34W-mutant protein in order to provide a theoretical basis for using H3F3A mutations as a diagnostic and differential-diagnostic tool for GCTBs. A total of 366 bone tumor cases were investigated. The cases involved 215 men and 151 women, whose median age was 29 years (3-84). The cases included GCTB (n=180), recurrent GCTB (n=19), GCTB with lung metas...
CONCLUSIONS: Without transcranial approaches requiring temporalis muscle dissection and orbitozygomatic osteotomy, the selection of ETOA or EEA based on a concept of a four-zone model with its epicenter around the optic nerve successfully provides a minimally invasive 360° circumferential access to the entire orbit with acceptable morbidity. PMID: 32977310 [PubMed - as supplied by publisher]
a Maestro Extraskeletal myxoid chondrosarcoma (EMC) is an ultra-rare mesenchymal neoplasm with uncertain differentiation, which arises mostly in the deep soft tissue of proximal extremities and limb girdles. EMC is marked by a translocation involving the NR4A3 gene, which can be fused in-frame with different partners, most often EWSR1 or TAF1. Although EMC biology is still poorly defined, recent studies have started shedding light on the specific contribution of NR4A3 chimeric proteins to EMC pathogenesis and clinical outcome. Standard treatment for localized disease is surgery, plus or minus radiation therapy with an ...
Publication date: Available online 17 September 2020Source: International Journal of Surgery Case ReportsAuthor(s): Muhammad Wahyudi, Andrian Astoguno Bayu Prakurso
Publication date: March 2021Source: Interdisciplinary Neurosurgery, Volume 23Author(s): Jing Liu, Xia Liu, Dahui Zuo, Yanhua Sun
Conclusion. Even more than during normal times, a multidisciplinary approach is mandatory to share the decision to modify a treatment strategy. Level of Evidence: 5
Publication date: Available online 10 September 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseAuthor(s): Megan E. Roche, Zhao Lin, Diana Whitaker-Menezes, Tingting Zhan, Karoly Szuhai, Judith V.M.G. Bovee, John A. Abraham, Wei Jiang, Ubaldo Martinez-Outschoorn, Atrayee Basu-Mallick
Cancer stem cells as a therapeutic target in 3D tumor models of human chondrosarcoma: An encouraging future for proline rich polypeptide‑1. Mol Med Rep. 2020 Sep 02;: Authors: Granger CJ, Hoyt AK, Moran A, Becker B, Sedani A, Saigh S, Conway SA, Brown J, Galoian K Abstract Chondrosarcoma is a malignant bone neoplasm that is refractory to chemotherapy and radiation. With no current biological treatments, mutilating surgical resection is the only effective treatment. Proline rich polypeptide 1 (PRP‑1), which is a 15‑amino acid inhibitor of mammalian target of rapamycin complex‑1 (mTORC1), has bee...
ConclusionUse of 3D customized implant helped us achieve two major goals in orthopaedic oncology —clear surgical resection and functional recovery with a good quality of life. Large studies with long-term follow-up are needed to reveal the value and future of 3D printing in orthopaedic oncology.